<DOC>
	<DOCNO>NCT02378844</DOCNO>
	<brief_summary>A prospective , double-blind , randomize , sham-controlled , multicentre investigation .</brief_summary>
	<brief_title>A Randomized , Multicentre , Double-blind , Parallel , Sham-controlled Study gammaCore</brief_title>
	<detailed_description>The study period begin four week run-in period , investigational treatment . The purpose run-in period observation baseline comparison . The run-in period , follow 12 week randomize period subject randomize ( 1:1 ) either active treatment sham ( inactive ) treatment . The randomized period follow 24 week open label period , subject sham treatment group switch treatment assignment receive gammaCore®-R gammaCore®-R continue receive active treatment .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>1 . Is ages 18 75 year . 2 . Has previously diagnose migraine ( without aura ) accordance International Classification Headache Disorders ( ICHD ) 3 Beta Classification criterion . 3 . Experience 5 12 migraine day per month ( last 4 month ) least 2 migraine last 4 hour . 4 . Has age onset migraine le 50 year old . 5 . Agrees use migraine prevention treatment ( include Botox injection ) and/or medication ( exclusive medication take acute relief migraine symptom ) . 6 . Agrees refrain initiate change type , dosage frequency prophylactic medication indication migraine opinion clinician may interfere study objective ( e.g . antidepressant , anti convulsant , beta blocker , etc. ) . 7 . Agrees use gammaCore®R device intend , follow requirement study include followup visit requirement , record require study data subject dairy , selfassessment questionnaire . 8 . Is able provide write Informed Consent . 1 . Has concomitant medical condition require oral injectable steroid study . 2 . Has history intracranial aneurysm , intracranial haemorrhage , brain tumour significant head trauma . 3 . Has structural abnormality gammaCore®R treatment site ( e.g lymphadenopathy previous surgery abnormal anatomy ) . 4 . Has pain gammaCore®R treatment site ( e.g.dysesthesia , neuralgia and/or cervicalgia ) . 5 . Has significant pain problem ( e.g.cancer pain , fibromyalgia head facial disorder ) opinion investigator may confound study assessment 6 . Has know suspect severe cardiac disease ( e.g . symptomatic coronary artery disease , prior myocardial infarction , congestive heart failure ( CHF ) ) . 7 . Has know suspect severe cerebrovascular disease , ( e.g . prior stroke transient ischemic attack , symptomatic carotid artery disease , prior carotid endarterectomy vascular neck surgery ) . 8 . Has abnormal baseline Electrocardiogram ( ECG ) e.g . second third degree heart block , prolong QT interval , atrial fibrillation , atrial flutter , history ventricular tachycardia ventricular fibrillation , clinically significant premature ventricular contraction ) . 9 . Has cervical vagotomy . 10 . Has uncontrolled high blood pressure ( systolic &gt; 160 diastolic &gt; 100 3 repeat measurement within 24 hour ) . 11 . Is currently implanted electrical and/or neurostimulator device ( e.g . cardiac pacemaker defibrillator , vagal neurostimulator , deep brain stimulator , spinal stimulator , bone growth stimulator cochlear implant , Sphenopalatine ganglion stimulator Occipital nerve stimulator ) . 12 . Has implant metal cervical spine hardware metallic implant near gammaCore®R stimulation site . 13 . Has know history suspicion secondary headache . 14 . Has history syncope ( within last five year ) . 15 . Has history seizure ( within last five year ) . 16 . Has know suspicion substance abuse addiction ( within last 5 year ) . 17 . Is use marijuana ( include medical marijuana ) indication , twice month . 18 . Currently take simple analgesic nonsteroidal antiinflammatory drug ( NSAIDs ) great 15 day per month triptans , ergot combine analgesic great 10 day per month headache body pain . 19 . Currently take prescription opioids great 2 day per month headache body pain . 20 . Has take medication migraine prophylaxis previous 30 day . 21 . Has previous diagnosis medication overuse headache ( MoH ) , revert episodic migraine within last 6 month . 22 . Meets ICHD3 Beta Classification criterion chronic migraine ( &gt; 15 headache day per month ) . 23 . Has fail adequate trial ( two month great ) least 3 class drug therapy prophylaxis migraine . 24 . Has surgery migraine prevention . 25 . Has undergone nerve block ( occipital ) head neck within last 2 month . 26 . Has receive Botox injection within last 6 month . 27 . Is pregnant think become pregnant study period , childbearing year unwilling use accept form birth control . 28 . Is participate therapeutic clinical investigation participate clinical trial precede 30 day . 29 . Belongs vulnerable population condition ability provide inform consent , comply followup requirement , provide self assessment compromise ( e.g . homeless , developmentally disabled prisoner ) . 30 . Is relative employee investigator clinical study site . 31 . Has psychiatric cognitive disorder and/or behavioural problem opinion clinician may interfere study . 32 . Has previously use gammaCore® device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>